article thumbnail

Tackling immune-mediated disease with CAR Tregs

European Pharmaceutical Review

Recognising the potential of CAR T cells to act as highly targeted therapeutics, several biotechnology companies – including Sangamo Therapeutics – have established development pipelines of CAR T regulatory cells (Tregs) that aim to tackle immune?mediated What are Tregs and how are they applicable to immune-mediated disease?

article thumbnail

Alzheimer’s vaccine granted Fast Track designation

European Pharmaceutical Review

AC Immune SA has received Fast Track designation from the US Food and Drug Administration (FDA) for its anti-amyloid beta (Abeta) active immunotherapy vaccine candidate for Alzheimer’s disease. The anti-Abeta therapy “specifically targets the most toxic forms of Abeta” according to Dr Andrea Pfeifer, CEO of AC Immune SA.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Science Summarised: All Things Meningioma

NF2 BioSolutions

Image Description] Journal title for the full open access published article summarised in this blog, titled “The clinical, genetic, and immune landscape of meningioma in patients with NF2 -schwannomatosis” by Gregory et al 2023.

article thumbnail

Top tweets: Covid-19 headed towards seasonality – and more

Pharmaceutical Technology

Laurie Garrett, a former senior fellow for global health at the Council on Foreign Relations (CFR), shared an article on discussions around Covid-19 being seasonal or a cyclical infection. In addition, immunity against the infection is found to wane for both previously infected individuals and the vaccinated.

article thumbnail

Is albumin the key to successful nasal vaccines?

European Pharmaceutical Review

The University of Minnesota researchers tested the technology on mice and non-human primates and found that the vaccine generated strong immune responses, paving the way for further study and development of nasal vaccines. This is because they can trigger immune responses in the primary areas of infection – the nose, mouth and lungs.

article thumbnail

Intratumoural viral delivery improves glioblastoma survival

European Pharmaceutical Review

The viral therapy “aims to awaken the patient’s immune system and trigger a healing from within,” Dr Fueyo commented. After injection, patients that respond well develop inflammation inside the tumour, triggering an immune response that first kills the virus.” This makes it difficult to treat the cancer with immunotherapy.

article thumbnail

Could personalised mRNA vaccine be first for cancer?

European Pharmaceutical Review

High-magnitude vaccine-induced T cell responses, the focus of the immune response analysis that included a new method to track vaccine-expanded clones, correlated with delayed PDAC recurrence. The personalised neoantigen vaccine was based on uridine mRNA–lipoplex nanoparticles. Rojas et al.